# of CUP | Molecule | Indication | Indication (short) | # of patients | Starting month of CUP |
---|---|---|---|---|---|
MO29499 | Alectinib | Adult patients with Anaplastic Lymphoma Kinase (ALK)-positive advanced Non-Small Cell Lung Cancer (NSCLC) | Non-Small Cell Lung Cancer 1 | 21° | March 2015 |
ML40066 | Alectinib | Adult patients with ALK-positive advanced NSCLC, previously treated with crizotinib | Non-Small Cell Lung Cancer 2 | 226° | May 2017 |
ML39740 | Atezolizumab | Adult patients with locally advanced or metastatic Urothelial Carcinoma (UC) after prior platinum-containing chemotherapy, or considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5 % | Urothelial Carcinoma | 222° | February 2017 |
AL41528 | Atezolizumab | Adult patients with locally advanced or metastatic NSCLC after prior chemotherapy (patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before) | Non-Small Cell Lung Cancer | 125° | June 2019 |
AL41712 | Atezolizumab | Adult patients with unresectable locally advanced or metastatic Triple-Negative Breast Cancer (TNBC), whose tumours have PD-L1 expression ≥ 1 % and who have not received prior chemotherapy for metastatic disease | Triple-Negative Breast Cancer | 41° | November 2019 |
M029476 | Cobimetinib | Adult patients with unresectable or metastatic Melanoma with a BRAF V600 mutation | Melanoma | 228° | May 2015 |
MA30130 | Ocrelizumab | Adult patients with Primary Progressive Multiple Sclerosis (PPMS) (in terms of disease duration and level of disability) and with imaging features characteristic of inflammatory activity | Primary Progressive Multiple Sclerosis | 1,045° | June 2017 |
AG40852 | Entrectinib | Adult and paediatric patients 12 years of age and older with solid tumours expressing a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor or who have no satisfactory treatment options | Solid tumours (NTRK) | 1 | August 2019 |
Adult patients with ROS1-positive advanced NSCLC, not previously treated with ROS1 inhibitors | Non-Small Cell Lung Cancer | 5° | |||
AG40661 | Polatuzumab Vedotin | Adult patients with relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.It is indicated in combination with the treatment of adult patients with bendamustine and rituximab | Diffuse Large B-Cell Lymphoma | 151° | May 2019 |
AG41381 | Risdiplam | Patients from 2 months old with 5q spinal muscular atrophy (SMA) Type 1, Type 2 or Type 3, or those who have up to 4 copies of SMN2 gene (Type 1) | Spinal Muscular Atrophy Type 1 | 28° | January 2020 |
AG42025 | Risdiplam | Patients from 2 months old with 5q Spinal Muscular Atrophy (SMA) Type 1, Type 2 or Type 3, or those who have up to 4 copies of SMN2 gene (Type 2) | Spinal Muscular Atrophy Type 2 | 31 | January 2020 |
AL41711 | Trastuzumab emtansine | Adult patients with HER2-positive, unresectable locally advanced or metastatic Breast Cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (i) received prior therapy for locally advanced or metastatic disease, or (ii) developed disease recurrence during or within six months of completing adjuvant therapy. | Breast Cancer | 621° | September 2019 |
Total # of patients | 2,745 ° 2,713 included in the analysis |